Onyx has goods to draw interest from other big drug makers
This article was originally published in Scrip
Executive Summary
Onyx Pharmaceuticals CEO Anthony Coles responded to an unsolicited bid from Amgen in a relatively short timeframe and with a bit of bravado, answering the big biotech company with a stern rejection and a swift plan to seek other potential buyers.